PharmaBlock announced the opening of its new R&D facility in West Chester, Pennsylvania. The facility expands the company's footprint in the US and enables more efficient process R&D services and fast delivery of clinical-stage GMP projects to global partners. Expanding Global Footprint and Enabling the Development of GMP Projects at PharmaBlock USA: The new West Chester site covers an area of four acres, with 30,000 ft2 of usable lab space.

The site has a well-established R&D infrastructure, including process R&D labs, GMP suites, clean rooms, and GMP analytical labs. The new site also enables flow chemistry, micro-packed bed hydrogenation, and solid-state chemistry capabilities. PharmaBlock took its first step in the US in 2012, with the sales and customer service office set up in the Bay Area of California.

In 2017, the company established the process R&D facility in Hatfield, Pennsylvania. With 15,000 ft2 of lab space, the Hatfield site is fully equipped with process R&D labs and GMP kilo-labs. Multiple API and GMP projects have been delivered to US-based clients from this site. The West Chester site is a crucial addition to enhance the delivery of clinical-stage API projects at PharmaBlock USA.

Furthermore, a GMP manufacturing facility for intermediates and APIs with reactors of 500 L to 2,000 L is also planned at the West Chester site, expected to operate in 2024. Expanding the global footprint is one of the initiatives that PharmaBlock has been working on to strengthen supply chain resilience. In addition to the US facilities, PharmaBlock has multiple R&D and GMP manufacturing facilities set up in China to provide fully integrated CMC solutions for intermediates, RSMs, APIs, and drug products from development to commercialization.

PharmaBlock is also seeking opportunities to expand its capabilities and capacity in other parts of the world.